Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$0.06 and traded as high as C$0.07. Hemostemix shares last traded at C$0.07, with a volume of 8,911 shares traded.
Hemostemix Stock Up 7.7%
The company has a debt-to-equity ratio of -66.09, a quick ratio of 0.48 and a current ratio of 0.24. The firm has a fifty day moving average price of C$0.06 and a 200 day moving average price of C$0.07. The firm has a market capitalization of C$14.35 million, a price-to-earnings ratio of -3.50 and a beta of 0.22.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Stories
- Five stocks we like better than Hemostemix
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
